Takahashi Hidenori, Satake Yugo, Shimizu Saori, Fujihara Satomi, Takano Syunsuke, Fukasawa Suzuko, Park Kaeyong, Toba Naoya, Yano Takahiko, Nagamatsu Hiroki, Hirose Ryutaro, Toyama-Kousaka Mio, Ota Shinichiro, Morikawa Miwa, Shinkai Masaharu
Department of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo 140-8522, Japan.
Department of Infection Control, Tokyo Shinagawa Hospital, Tokyo 140-8522, Japan.
Medicina (Kaunas). 2025 May 21;61(5):937. doi: 10.3390/medicina61050937.
: Group A (GAS) is a leading cause of acute pharyngitis with seasonal outbreaks. The coronavirus disease 2019 (COVID-19) pandemic significantly altered respiratory infection trends; however, its impact on GAS pharyngitis (GAS-P) incidence remains unclear. Additionally, data on co-infections with GAS and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are limited. In this study, temporal trends in GAS-P incidence and characteristics of GAS-SARS-CoV-2 co-infections in Japan were examined. : In this observational study, data from patients who visited the Tokyo Shinagawa Hospital between January 2019 and December 2024 were retrospectively analyzed. Data on GAS and SARS-CoV-2 test results and patient demographics were extracted from medical records. The study period was categorized based on COVID-19-related public health measures as follows: pre-COVID-19 social period (January 2019-April 2020), restricted social period (May 2020-April 2023), and post-restriction period (May 2023-December 2024). GAS incidence stratified by sex, age, and period was calculated. Clinical characteristics of patients co-infected with GAS and SARS-CoV-2 were analyzed. : Among 4837 GAS tests, 463 (9.6%) were positive. GAS positivity rates varied significantly: 11.4% (pre-COVID-19), 7.1% (restricted social period), and 12.6% (post-restriction period; < 0.001). The proportion of pediatric cases decreased significantly during the restricted social period (24.8-5.3%) before rising sharply in the post-restriction period (47.1%, < 0.001). Among 151 patients tested for GAS and SARS-CoV-2, 14 (9.3%) had co-infections, which were identified exclusively after July 2022. Most patients exhibited mild symptoms, primarily fever and sore throat, with decreased lymphocyte counts despite normal white blood cell counts. : In our cohort, the incidence of GAS pharyngitis temporarily declined during COVID-19-related public health measures and subsequently increased, particularly among children, after restrictions were lifted. Limited testing may contribute to the underdiagnosis of GAS-SARS-CoV-2 co-infections. Further large-scale studies are warranted to assess microbial interactions, disease severity, and long-term outcomes.
A组链球菌(GAS)是急性咽炎季节性暴发的主要病因。2019冠状病毒病(COVID-19)大流行显著改变了呼吸道感染趋势;然而,其对GAS咽炎(GAS-P)发病率的影响仍不明确。此外,关于GAS与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)合并感染的数据有限。在本研究中,调查了日本GAS-P发病率的时间趋势以及GAS-SARS-CoV-2合并感染的特征。
在这项观察性研究中,对2019年1月至2024年12月期间就诊于东京品川医院的患者数据进行了回顾性分析。从病历中提取了GAS和SARS-CoV-2检测结果以及患者人口统计学数据。研究期间根据与COVID-19相关的公共卫生措施分为以下几类:COVID-19前社交期(2019年1月至2020年4月)、社交受限期(2020年5月至2023年4月)和限制解除期(2023年5月至2024年12月)。计算按性别、年龄和时期分层的GAS发病率。分析了GAS和SARS-CoV-2合并感染患者的临床特征。
在4837次GAS检测中,463次(9.6%)呈阳性。GAS阳性率差异显著:11.4%(COVID-19前)、7.1%(社交受限期)和12.6%(限制解除期;P<0.001)。儿科病例的比例在社交受限期显著下降(24.8%-5.3%),然后在限制解除期急剧上升(47.1%,P<0.001)。在151名接受GAS和SARS-CoV-2检测的患者中,14名(9.3%)合并感染,均在2022年7月之后确诊。大多数患者表现为轻度症状,主要是发热和咽痛,白细胞计数正常但淋巴细胞计数下降。
在我们的队列中,GAS咽炎的发病率在与COVID-19相关的公共卫生措施期间暂时下降,随后在限制解除后上升,尤其是在儿童中。检测有限可能导致GAS-SARS-CoV-2合并感染的诊断不足。有必要进行进一步的大规模研究,以评估微生物相互作用、疾病严重程度和长期预后。